6.26
+0.0227(+0.36%)
Currency In USD
| Previous Close | 6.24 |
| Open | 6.2 |
| Day High | 6.52 |
| Day Low | 6.13 |
| 52-Week High | 54.95 |
| 52-Week Low | 5.01 |
| Volume | 23,673 |
| Average Volume | 210,327 |
| Market Cap | 1.6M |
| PE | -0.09 |
| EPS | -66.85 |
| Moving Average 50 Days | 8.43 |
| Moving Average 200 Days | 17.36 |
| Change | 0.02 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.39 as of May 09, 2025 at a share price of $6.263. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $2.64 as of May 09, 2025 at a share price of $6.263.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to releas
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire Inc.
Apr 30, 2025 11:30 AM GMT
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
GlobeNewswire Inc.
Apr 10, 2025 11:30 AM GMT
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website